Thomson PD, Slevin PN, Baines H, Betts G, et al. Randomised phase III trial of the hypoxia modifier nimorazole added to radiotherapy with benefit assessed in hypoxic head and neck cancers determined using a gene signature (NIMRAD). Int J Radiat Oncol Biol Phys 2023 Dec 8:S0360-3016(23)08184.
PMID: 38072326